Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jul;40(7):494-502.
doi: 10.1136/jmg.40.7.494.

Visceral manifestations in hereditary haemorrhagic telangiectasia type 2

Affiliations

Visceral manifestations in hereditary haemorrhagic telangiectasia type 2

S A Abdalla et al. J Med Genet. 2003 Jul.

Abstract

Hereditary haemorrhagic telangiectasia (HHT) is a genetic vascular disorder characterised by epistaxis, telangiectases, and visceral manifestations. The two known disease types, HHT1 and HHT2, are caused by mutations in the endoglin (ENG) and ALK-1 genes, respectively. A higher frequency of pulmonary arteriovenous malformations (AVMs) has been reported for HHT1 while HHT2 is thought to be associated with a lower penetrance and milder disease manifestations. In this study, we present 10 families with an ALK-1 genotype. Visceral manifestations were detected in 24 (26%) of the 93 HHT2 patients from nine of the families and included gastrointestinal bleeding (14%), intrahepatic shunts (6%), and AVMs in the lung (4%) and brain (3%). Gastrointestinal bleeding, the most frequent visceral manifestation, was reported in six of the 10 families, mostly in patients over the age of 50. These patients also had frequent epistaxis and suffered from anaemia, often requiring blood transfusions. The identification of ALK-1 mutations in subjects with a suspected diagnosis and without clinical signs of HHT argue in favour of a molecular diagnosis. We also analysed the data published on 44 families with HHT2 and conclude that visceral manifestations occur in 26 of these families and affect 30% of HHT2 patients. This is considered an underestimate given incomplete and variable screening for lung, brain, and/or liver involvement in different clinical centres. These findings, however, stress the need for an early diagnosis of HHT that can be useful for the early control of associated visceral involvement.

PubMed Disclaimer

References

    1. Gastroenterology. 1993 Aug;105(2):482-7 - PubMed
    1. Am J Gastroenterol. 1993 Jul;88(7):1116-9 - PubMed
    1. Chest. 1994 Nov;106(5):1387-90 - PubMed
    1. AJR Am J Roentgenol. 1994 Nov;163(5):1105-10 - PubMed
    1. Am J Med Genet. 1994 Aug 15;52(2):252-3 - PubMed

Publication types

MeSH terms

Substances